|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Experimental study on therapeutic effect of in vivo expression of Cell Ⅰ-Hep Ⅱ recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma显示文摘AIM: To investigate the inhibitory effect of in vivoexpression of expressing plasmid pCH510 of recombinant fibronectin polypeptide (CH50) on hepatocellular carcinoma and the improved therapeutic effect of pCH510 in combination with chemotherapeutic agents and Hsp70-H22 hepatocarcinoma antigen peptide on tumor.METHODS: Mice were inoculated with H22 hepatccarcinoma cells. The chemotactic effect of the expression of plasmid pCH510 on immunocytes was observed after in vivo transfection, tissue slicing and HE staining. Inhibitory effect of transfection with pCH510 on routine tumor originatedfrom different inoculative doses was observed. The inhibitory effect of immediate transfection with pCH510 after chemotherapy on tumor was compared with that of transfection 5 days after chemotherapy. The change of function and amount of mouse peritoneal macrophages and the peripheral blood immunocytes resulted from administration of chemotherapeutic agents were detected. The peptides mixture was prepared from H22 hepatocarcinoma cells, pCH510 + Hsp70-H22 antigen peptides were injected into tumor-bearing mice with or without chemotherapy, to observe the inhibitory effects on tumor.RESULTS: At the tumor tissue site injected with pCH510,there were a great number of immunocytes which mainly were macrophages, lymphocytes and neutrophils.Transfection of plasmid pCH510 inhibited significantly the murine tumor induced by different inoculative doses. The inhibitory effect was negatively correlated with the inoculative dose. The therapeutic effect was not improved by immediate transfection with pCH510 after chemotherapy, but was significantly improved by transfection with pCH510 5 days after chemotherapy. Chemotherapeutic agent decreased the number of immunocytes and suppressed their activation in vivo. After injection of drug, the amount of immunocytes was the lowest from d 1 to d 3 and returned to normal level on the 10th day. Transfection with plasmid pCH510 alone could inhibit tumor induced by the inoculation with 10^4 H22 cells. The tumor originated from the inoculation with 10^5 H22 cells was inhibited by pCH510+Hsp70-H22 antigen peptides and that from the inoculation with 10^6 H22 cells was inhibited by pCH510+HspT0-H22 antigen peptides in combination with chemotherapeutic agents.CONCLUSION: In vivo expression of pCH510 recruits immune cells, inhibits tumor growth, and enhances the efficacy of chemotherapy, But the proper timing of combining chemotherapy with pCH510 must be taken into great account, The synergism of pCH510 and Hsp70-H22 peptides can improve the efficacy, which could be further enhanced if they are used following chemotherapy, Chemotherapeutic agent + pCH510 + Hsp70-H22 peptides is a promising therapeutic approach of combination treatment of tumor, | Gui-Mei Zhang Yan Yang Bo Huang Hui Xiao Dong Li Zuo-Hua Feng Department of Biochemistry and Molecular Biology,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei Province,China | 2003 | World Journal of Gastroenterology2003，9，9： | 13 |
| 2 | Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma显示文摘AIM: To study the antitumor effect of combined gene therapy of endostatin and interleukin 12 (IL-12) with polyvinylpyrrolidone (PVP) on mouse transplanted hepatoma.METHODS: Mouse endostatin eukaryotic plasmid (pSecES) with a mouse Igk signal sequence inside and mouse IL-12 eukaryotic plasmid (pmIL-22) were transfected into BHK-22cells respectively. Endostatin and IL-22 were assayed by ELISA from the supernant and used to culture endothelial cells and spleen lymphocytes individually. Proliferation of the latter was evaluated by M-I-r. H22 cells were inoculated into the leg musde of mouse, which was injected intratumorallywith pSecES/PVP, pmIL-12/PVP or pSecES+pmIL-12/PVPrepeatedly. Tumor weight, serum endostatin and serumIL-22 were assayed. Tumor infiltrating lymphocytes, tumormicrovessel density and apoptosis of tumor cells were also displayed by HE staining, CD32 staining and TUNEL.RESULTS: Endostatin and IL-12 were secreted after transfection, which could inhibit the proliferation of endothelial cells or promote the proliferation of spleen lymphocytes.Tumor growth was highly inhibited by 92.8% after injection of pSecES+pmIL-i2/PVP accompanied by higher serum endostatin and IL-22, more infiltrating lymphocytes, fewertumor vessels and more apoptosis cells compared with injection of pSecES/PVP, pmIL-i2/PVP or vector/PVP.CONCLUSION: Mouse endostatin gene and IL-12 gene can be expressed after intratumoral injection with PVP.Angiogenesis of hepatoma can be inhibited synergisticly,lymphocytes can be activated to infiltrate, and tumor cells are induced to apoptosis. Hepatoma can be highly inhibited or eradiated. | Pei-YuanLi Ju-ShengLin Zuo-HuaFeng Yu-FeiHe He-JunZhou XinMa Xiao-KunCai De-AnTian | 2004 | World Journal of Gastroenterology2004，10，15： | 7 |
| 3 | Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model显示文摘rAAV mediated endostatin gene therapy has beenexamined as a new method for treating cancer. However,a sustained and high protein delivery is required to achievethe desired therapeutic effects. We evaluated the impactof topoisomerase inhibitors in rAAV delivered endostatingene therapy in a liver tumor model. | SungYiHong MyunHeeLee WooJinHyung SungHoonNoh SeungHoChoi Kyung Sup Kim HyunCheolJung JaeKyungRoh | 2004 | World Journal of Gastroenterology2004，10，8： | 6 |
| 4 | 蚓激酶基因的人工合成及山羊乳腺表达显示文摘为了实现蚓激酶在真核细胞的高效稳定表达 ,人工合成了全长 849bp ,不含罕用密码子的蚓激酶F Ⅲ 1cDNA序列 ,并以其为目的基因 ,构建以山羊β 酪蛋白启动子为上游调控序列的乳腺组织特异性表达载体pBLK和重组逆转录病毒表达载体pLN bCP LK。质粒pBLK 40 0 μg直接注入稳定泌乳期奶山羊乳腺 ,以纤维蛋白平板溶圈法 (FAPA)检测奶样纤溶活性。结果显示 ,注射后 3~ 60h ,奶样有明显纤溶活性 ,其中 6~ 9h活性最高。脂质体介导质粒pLN bCP LK转染PA31 7细胞系 ,5 0 0mg LG41 8筛选后获得 4株高产毒细胞系 ,产毒滴度达 1× 1 0 4~ 1× 1 0 5CFU ml水平。产毒细胞上清 1 0ml直接注入临产前两周的山羊乳腺 ,隔日以等量再注 1次 ,产羔后其奶样即有明显纤溶活性 ,注后第 | 张守峰 扈荣良 范志强 姚汝强 梁慧颖 涂长春 | 2004 | 中国生物工程杂志2004，24，9： | 6 |
| 5 | 重组腺相关病毒载体在肝疾病基因治疗中的应用及局限性显示文摘基因治疗(gene therapy)是近十年来随着现代分子生物学技术的发展而诞生的新的生物医学治疗技术。重组腺病毒伴随病毒是一种具有开发潜质的病毒载体,因此近年来对它的研究很是受人关注。肝炎、肝硬化、肝癌在我国乃至全世界是严重损害人们的健康,据此,国内外的研究人员对rAAV在肝疾病基因治疗方面做了大量的工作,本文对rAAV在肝疾病基因治疗中的应用和局限性研究进行综述。 | 赵丽 韩金祥 鲁艳芹 高刚 | 2009 | 现代生物医学进展2009，9，12： | 2 |
| 6 | GnRH类似物诱导肝癌细胞凋亡的体外研究显示文摘目的:研究GnRH类似物阿拉瑞林诱导体外培养的人肝癌细胞株SMMC-7721发生凋亡的作用,为GnRH类似物用于肝癌的内分泌治疗提供实验资料。方法:采用MTT法、形态学透射电镜观察和末端脱氧核苷酸标记法观察被阿拉瑞林处理后的SMMC-7721细胞的形态学和生化等指标的变化。结果:MTT法研究结果表明阿拉瑞林在10^(-9)mol/L浓度时即可诱导7721细胞凋亡,并呈量-效效应。透射电镜下可观察到时期凋亡细胞和晚期凋亡细胞以及核染色质浓缩并见凋亡小体。末端脱氧核苷酸转移标记法进一步证实阿拉瑞林可以诱导肝癌细胞凋亡并可见调亡小体;与对照组相比,阿拉瑞林处理后TUNEL凋亡指数显著增加(0.29 ± 0.06 vs0.11±0.03,P<0.05)。结论:GnRH类似物可诱导体外培养的肝癌细胞株SMMC-7721发生凋亡,从而提示GnRH类似物对人肝细胞性肝癌具有潜在的治疗作用。 | 刘庆元 窦科峰 张金山 孙岚 黄鲁豫 张远强 | 2003 | 世界华人消化杂志2003，11，9： | 1 |
| 7 | 内皮抑素在肝癌基因治疗中的应用及其进展显示文摘 | 陈钢 易继林 | 2006 | 肝胆外科杂志2006，14，2： | 0 |
| 8 | 内皮抑素治疗肿瘤的研究和进展显示文摘 | 刘雷 王本忠 | 2006 | 安徽医学2006，27，2： | 0 |
| 9 | 内皮抑素与消化系肿瘤显示文摘内皮抑素是特异性的血管内皮细胞生长抑制因子之一 ,能够显著抑制肿瘤血管增生并诱导肿瘤细胞凋亡。研究表明 ,内皮抑素具有高效抑瘤特性 ,低毒副作用 ,无耐药性等特点。内皮抑素在消化系肿瘤的应用 ,为肿瘤的抗血管生成治疗和血管靶向基因治疗提供了新的广阔前景。 | 刘祺 周建平 李永国 | 2004 | 中国普通外科杂志2004，13，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员